Qilian International Holding Group Limited (BGM)vsHaleon plc (HLN)
BGM
Qilian International Holding Group Limited
$0.29
-10.49%
HEALTHCARE · Cap: $58.22M
HLN
Haleon plc
$9.12
+1.79%
HEALTHCARE · Cap: $40.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 36826% more annual revenue ($11.03B vs $29.87M). HLN leads profitability with a 15.1% profit margin vs 0.0%. HLN earns a higher WallStSmart Score of 63/100 (C+).
BGM
Hold39
out of 100
Grade: F
HLN
Buy63
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -0.8% — below average capital efficiency
Expensive relative to growth rate
0.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : BGM
The strongest argument for BGM centers on Price/Book, Debt/Equity, Altman Z-Score. Revenue growth of 13.9% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : BGM
The primary concerns for BGM are EPS Growth, Market Cap, Profit Margin.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BGM carries more volatility with a beta of 1.46 — expect wider price swings.
BGM is growing revenue faster at 13.9% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (63/100 vs 39/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Qilian International Holding Group Limited
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company is headquartered in Jiuquan, the People's Republic of China.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, formed as a spin-off from GlaxoSmithKline, that specializes in delivering innovative health solutions through its extensive portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. With a focus on key health segments such as oral care, pain relief, and dietary supplements, Haleon leverages strong brand recognition to meet the evolving needs of consumers. The company's commitment to sustainability and continuous innovation positions it strategically for long-term growth, aimed at enhancing health outcomes and delivering shareholder value through targeted investments and ongoing product development.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?